دورية أكاديمية

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial

التفاصيل البيبلوغرافية
العنوان: Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
المؤلفون: Samuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, Ian D Davis, Andrew M Scott, Rodney J Hicks, Ur Metser, Sue Chua, Reena Davda, Shonit Punwani, Heather Payne, Nina Tunariu, Bao Ho, Sympascho Young, Mahukpe Narcisse Ulrich Singbo, Glenn Bauman, Louise Emmett, Frédéric Pouliot
المصدر: Cancer Imaging, Vol 23, Iss 1, Pp 1-7 (2023)
بيانات النشر: BMC, 2023.
سنة النشر: 2023
المجموعة: LCC:Medical physics. Medical radiology. Nuclear medicine
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Prostate cancer, Biochemical recurrence, Molecular imaging, PSMA, Choline, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background The impact of molecular imaging (MI) on patient management after biochemical recurrence (BCR) following radical prostatectomy has been described in many studies. However, it is not known if MI-induced management changes are appropriate. This study aimed to determine if androgen deprivation therapy (ADT) management plan is improved by MI in patients who are candidates for salvage radiation therapy. Methods Data were analyzed from the multicenter prospective PROPS trial evaluating PSMA/Choline PET in patients being considered for salvage radiotherapy (sRT) with BCR after prostatectomy. We compared the pre- and post-MI ADT management plans for each patient and cancer outcomes as predicted by the MSKCC nomogram. A higher percentage of predicted BCR associated with ADT treatment intensification after MI was considered as an improvement in a patient’s management. Results Seventy-three patients with a median PSA of 0.38 ng/mL were included. In bivariate analysis, a positive finding on MI (local or metastatic) was associated with decision to use ADT with an odds ratio of 3.67 (95% CI, 1.25 to 10.71; p = 0.02). No factor included in the nomogram was associated with decision to use ADT. Also, MI improved selection of patients to receive ADT based on predicted BCR after sRT : the predicted nomogram 5-year biochemical-free survivals were 52.5% and 43.3%, (mean difference, 9.2%; 95% CI 0.8 to 17.6; p = 0.03) for sRT alone and ADT±sRT subgroups, while there was no statistically significant difference between subgroups before MI. Conclusions PSMA and/or Choline PET/CT before sRT can potentially improve patient ADT management by directing clinicians towards more appropriate intensification.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1470-7330
Relation: https://doaj.org/toc/1470-7330
DOI: 10.1186/s40644-023-00570-x
URL الوصول: https://doaj.org/article/30cb46152e074b16adc42dda02908660
رقم الأكسشن: edsdoj.30cb46152e074b16adc42dda02908660
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14707330
DOI:10.1186/s40644-023-00570-x